148 related articles for article (PubMed ID: 34979089)
21. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
Grem JL
Invest New Drugs; 2000 Nov; 18(4):299-313. PubMed ID: 11081567
[TBL] [Abstract][Full Text] [Related]
22. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
23. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
24. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
25. Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Liu Z; Xie W; Li M; Teng N; Liang X; Zhang Z; Yang Z; Wang X
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):480-486. PubMed ID: 28667794
[TBL] [Abstract][Full Text] [Related]
26. Covalently mucoadhesive amphiphilic prodrug of 5-fluorouracil for enhanced permeation and improved oral absorption.
Liu Y; Zhao D; Sun M; Wei W; Wang Y; Zhou J; Zhang R; Wang J; Zhang H; He Z; Kan Q; Sun J
Drug Deliv Transl Res; 2018 Jun; 8(3):645-656. PubMed ID: 29532356
[TBL] [Abstract][Full Text] [Related]
27. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
28. Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Sommer J; Mahli A; Freese K; Schiergens TS; Kuecuekoktay FS; Teufel A; Thasler WE; Müller M; Bosserhoff AK; Hellerbrand C
Oncotarget; 2017 Feb; 8(8):13059-13072. PubMed ID: 28055957
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
Technol Eval Cent Assess Program Exec Summ; 2010 Aug; 24(13):1-3. PubMed ID: 21114065
[No Abstract] [Full Text] [Related]
30. A review of analytical methods for the determination of 5-fluorouracil in biological matrices.
Breda M; Barattè S
Anal Bioanal Chem; 2010 Jun; 397(3):1191-201. PubMed ID: 20383700
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.
Cao D; Ziemba A; McCabe J; Yan R; Wan L; Kim B; Gach M; Flynn S; Pizzorno G
Mol Cancer Ther; 2011 Dec; 10(12):2330-9. PubMed ID: 21954436
[TBL] [Abstract][Full Text] [Related]
32. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
33. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.
Arellano M; Malet-Martino M; Martino R; Gires P
Br J Cancer; 1998; 77(1):79-86. PubMed ID: 9459149
[TBL] [Abstract][Full Text] [Related]
34. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
[TBL] [Abstract][Full Text] [Related]
35. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
36. 5-Fluorouracil derivatives: a patent review.
Álvarez P; Marchal JA; Boulaiz H; Carrillo E; Vélez C; Rodríguez-Serrano F; Melguizo C; Prados J; Madeddu R; Aranega A
Expert Opin Ther Pat; 2012 Feb; 22(2):107-23. PubMed ID: 22329541
[TBL] [Abstract][Full Text] [Related]
37. Fluorouracil and the new oral fluorinated pyrimidines.
Kuhn JG
Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
[TBL] [Abstract][Full Text] [Related]
38. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
39. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
40. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
